AM-5992 / Amgen - LARVOL DELTA

Harnessing glycolysis- and cholesterol synthesis-related genes for prognostic modeling in lung adenocarcinoma. (PubMed, Comput Methods Biomech Biomed Engin) - "Drug sensitivity analysis suggested that amonafide, AM-5992, and AZD-3147 may serve as potential therapeutic candidates. In conclusion, this model enables precise survival prediction and provides valuable insights for personalized immunotherapy and targeted treatment."

IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Breast Cancer Prognostic Model Based on Folic Acid Metabolism-Related Genes to Reveal the Immune Landscape. (PubMed, Horm Metab Res) - "AM-5992 and 5-fluorodeoxyuridine 10mer may be potential BC drugs. This FMR-based model can accurately predict BC prognosis, offering a clinical reference."

Biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Women's Health • BRCA • IFNG • NFKB2 • SERPINA3

FERMT1 Is a Prognostic Marker Involved in Immune Infiltration of Pancreatic Adenocarcinoma Correlating with mA Modification and Necroptosis. (PubMed, Genes (Basel)) - "Finally, FERMT1 overexpression may be sensitive to chemotherapy drugs such as Palbociclib, AM-5992 and TAE-226. FERMT1 can serve as a diagnostic and prognostic marker of PAAD, which is connected with immune cell infiltration and the modulation of mA and necroptosis."

Biomarker • Journal • Gastrointestinal Cancer • Hepatology • Immune Modulation • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • FERMT1